Everence Capital Management Inc. Reduces Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Everence Capital Management Inc. cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 43.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 11,530 shares of the medical device company’s stock after selling 8,940 shares during the quarter. Everence Capital Management Inc.’s holdings in DexCom were worth $897,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Sachetta LLC increased its position in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 171 shares during the last quarter. Versant Capital Management Inc bought a new stake in shares of DexCom during the 4th quarter valued at about $25,000. Riverview Trust Co increased its position in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the last quarter. RPg Family Wealth Advisory LLC bought a new position in shares of DexCom in the 3rd quarter worth approximately $57,000. Finally, Covestor Ltd boosted its holdings in shares of DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after buying an additional 335 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on DXCM. Citigroup upped their target price on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Raymond James decreased their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Royal Bank of Canada reduced their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Sanford C. Bernstein lifted their price objective on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Finally, Oppenheimer reduced their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus target price of $98.00.

DexCom Stock Up 3.3 %

Shares of DXCM opened at $81.07 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock has a market capitalization of $31.67 billion, a price-to-earnings ratio of 48.55, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The business’s 50 day simple moving average is $76.12 and its 200-day simple moving average is $80.54.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.30% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.